Source comparison
Peptide Type, Mechanism, Dosing Window, and Research Outcomes Comparison
CJC-1295 + Ipamorelin GHRH receptor + ghrelin receptor dual agonism. Increases both GH pulse amplitude and frequency Pre-sleep (10–11 PM) or fasted morning (6–7 AM) 8.2–11.7% reduction vs baseline Gold standard combination. Synergistic GH release without corti
This comparison does not assign a generated winner or score.
- CJC-1295 + Ipamorelin
- GHRH receptor + ghrelin receptor dual agonism. Increases both GH pulse amplitude and frequency
- Pre-sleep (10–11 PM) or fasted morning (6–7 AM)
- 8.2–11.7% reduction vs baseline
- Gold standard combination. Synergistic GH release without cortisol elevation, well-tolerated across demographic groups
- GHRP-2
- Ghrelin receptor agonist. Stimulates GH secretion with moderate ghrelin-like appetite effects
- 30 min pre-meal (leverages postprandial GH window)
- 6.4–9.1% reduction vs baseline
- Strong GH response but may increase appetite via ghrelin pathway. Requires dietary control during protocol
- Hexarelin
- Ghrelin receptor superagonist. Highest GH release per dose but desensitises receptors with chronic use
- Pulsed dosing (2 weeks on, 1 week off)
- 7.8–10.3% reduction (pulsed protocols only)
- Potent but self-limiting. Receptor downregulation after 10–14 days requires cycling, not suitable for continuous protocols
- Tesamorelin
- Selective GHRH analogue. FDA-approved for lipodystrophy, targets visceral adipose specifically
- Daily subcutaneous injection (consistent timing)
- 12.4–15.2% visceral fat reduction
- Clinical-grade option with most robust safety data. Specifically reduces visceral adiposity, limited effect on subcutaneous fat